Press release
Compugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients
COM701 in combination with nivolumab demonstrated encouraging 12% ORR in 3L+ MSS-CRC patients with liver metastases, compared to 0% ORR historically for other
About this update from Compugen Ltd.
[{"type":"text","content":"COM701 in combination with nivolumab demonstrated encouraging 12% ORR in 3L+ MSS-CRC patients with liver metastases, compared to 0% ORR historically for other immunotherapies in a U.S. patient populationTranslational data showed potent immune activation in the tumor microenvironment (TME) in patients responding to treatment, atypical of immunotherapy in cold tumors like MSS-CRCFurther clinical evaluation of COM701 + anti-PD-1 in combination with COM902 planned in MSS-CRC patientsManagement will discuss the preliminary data to be presented at SITC as part of the Q3 earnings call on Monday, November 14, 2022, at 8:30 am ETHOLON, Israel, Nov. 7, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today publication of an abstract on preliminary data showing anti-tumor activity and potent immune modulation with the combination of COM701 and nivolumab in metastatic MSS-CRC patients. The data will be presented as an oral presentation by Michael Overman, M.D., University of Texas MD Anderson Cancer Center at the annual meeting of the Society for Immunotherapy of Cancer (SITC) on November 10, 2022 in Boston, MA.\n\"MSS-CRC is a cold tumor that is typically not responsive to immunotherapy, especially in MSS-CRC patients with liver metastases representing about 70% of all CRC patients,\" said CRC expert and presenting author, Dr. Michael Overman. \"The data we will present at SITC, are encouraging and address this non-immune responsive subset of CRC. Adding COM701 to nivolumab resulted in a response rate of 9% in 22 MSS-CRC patients with two partial responses occurring in 17 patients with liver metastases. This stands in contrast to other novel immunotherapy combinations where responses in MSS-CRC patients with liver metastases have been extremely rare to non-existent. I was particularly excited to see that the responses were supported by robust translational data, clearly showing immune activation that reflects the mechanism of action from the addition of COM701 to nivolumab. While the numbers of patients were small, the data are encouraging and warrant further evaluation. I look forward to investigating COM701 and an anti-PD-1 in triple combination with Compugen's anti-TIGIT, COM902 in a similar patient population.\"\nAnat Cohen-Dayag,...